Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of ALXN2220 in ATTR-CM
NCT07789483Phase 3Not yet recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Nov 2027
- Primary completion
- Jul 2030
- Countries
- 27
01
Overview
Phase 3, open-label, single-arm trial of cliramitug in transthyretin amyloid cardiomyopathy (ATTR-CM), sponsored by Alexion Pharmaceuticals. Primary endpoint: Treatment-Emergent Adverse Events up to 24 months. Planned start Nov 2027; status: not yet recruiting.
02
Drugs
cliramitug
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT07789483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07789483.